V212
Biological
Merck Sharp & Dohme Corporation
Total Payments
$1.2M
Transactions
718
Doctors
10
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $116,777 | 5 | 0 |
| 2018 | $47,196 | 87 | 4 |
| 2017 | $992,631 | 626 | 10 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 685 | 97.4% |
| Consulting Fee | $30,188 | 33 | 2.6% |
Payments by Type
Research
$1.1M
685 transactions
General
$30,188
33 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy | Merck Sharp & Dohme Corporation | $1.0M | 0 |
| A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants HCTs | Merck Sharp & Dohme Corporation | $90,993 | 0 |
Top Doctors Receiving Payments for V212
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Anderson, IN | $1.1M | 685 |
| , MD | Hematology & Oncology | Minneapolis, MN | $7,613 | 6 |
| Janice Brown | — | Stanford, CA | $4,950 | 2 |
| , M.D | Internal Medicine | Rochester, MN | $4,500 | 3 |
| , M.D | Infectious Disease | Baltimore, MD | $4,125 | 3 |
| , MD | Infectious Disease | Los Angeles, CA | $2,450 | 6 |
| , M.D | Pediatric Infectious Diseases | Stanford, CA | $2,363 | 5 |
| Kathleen Mullane | Infectious Disease | Burr Ridge, IL | $1,400 | 3 |
| , MD MPH | Infectious Disease | Seattle, WA | $1,125 | 1 |
| , MD | Infectious Disease | Seattle, WA | $962.50 | 2 |
| , M.D., MPH | Hematology & Oncology | Houston, TX | $700.00 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $1.2M
- Total Doctors 10
- Transactions 718
About V212
V212 is a biological associated with $1.2M in payments to 10 healthcare providers, recorded across 718 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2019. In 2019, $116,777 was paid across 5 transactions to 0 doctors.
The most common payment nature for V212 is "Unspecified" ($1.1M, 97.4% of total).
V212 is associated with 2 research studies, including "A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy" ($1.0M).